OTCMKTS:EUCRU Eucrates Biomedical Acquisition (EUCRU) Stock Price, News & Analysis $10.02 +0.01 (+0.10%) As of 04/26/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Eucrates Biomedical Acquisition Stock (OTCMKTS:EUCRU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get EUCRU alerts:Sign Up Key Stats Today's Range$10.01▼$10.0250-Day Range$10.02▼$10.0252-Week Range$9.76▼$10.66Volume21,500 shsAverage Volume1,921 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York. Read More Receive EUCRU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address EUCRU Stock News HeadlinesPsyence Biomed halts Clairvoyant Therapeutics acquisitionOctober 6, 2024 | investing.comEucrates Biomedical Acquisition announces liquidationApril 11, 2023 | seekingalpha.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Eucrates Biomedical Acquisition Corp. Announces LiquidationApril 11, 2023 | finance.yahoo.comBiomedical Sensors Market will surpass USD 21.3 billion by 2030 at a CAGR of 16% till 2030 : GreyViewsJanuary 30, 2023 | finance.yahoo.comLove Island 2023: First contestant revealed as stunning biomedical student TanyaJanuary 25, 2023 | mirror.co.ukMBiomedical EngineerJanuary 11, 2023 | money.usnews.comCenterline Biomedical announces Gulam Khan as Chief Executive OfficerOctober 6, 2022 | markets.businessinsider.comSee More Headlines EUCRU Stock Analysis - Frequently Asked Questions How have EUCRU shares performed this year? Eucrates Biomedical Acquisition's stock was trading at $10.02 at the beginning of 2025. Since then, EUCRU shares have increased by 0.0% and is now trading at $10.02. How do I buy shares of Eucrates Biomedical Acquisition? Shares of EUCRU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorFinance Industry Shell Companies Sub-IndustryTrading Current SymbolOTCMKTS:EUCRU CIK1822929 WebN/A Phone(212) 710-5220FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:EUCRU) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eucrates Biomedical Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eucrates Biomedical Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
